Research
Hormonal
During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.
If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.
ModerateQualifiesMEDIUM confidence
five participants in the stable phase reported that hunger had returned over time, but it was less than pre- treatment levels
Why this rating
Based on qualitative self-report from a subset of patients (5/15 in stable phase).
Source
Changes in Eating Behaviour During Treatment With Obesity Medications
Ming Chuen Chong et al. · Clinical Obesity · 2025
DOI 10.1111/cob.70065
cross_sectional · n=31Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →